Shandong New Time Pharmaceutical Co., LTD
Quick facts
Marketed products
- Huazhi Rougan granule · Hepatology / Traditional Chinese Medicine
Huazhi Rougan granule is a traditional Chinese medicine formulation designed to support liver function and promote hepatic health through its herbal constituents. - Huazhi Rougan Granule Placebo granule
This is a placebo granule formulation with no active pharmaceutical ingredient and therefore no mechanistic action.
Phase 3 pipeline
- F027 · Diabetes
F027 is a small molecule that targets the SGLT2 receptor. - H02+CHOP · Oncology
H02+CHOP is a chemotherapy combination regimen that uses doxorubicin, cyclophosphamide, vincristine, and prednisone to inhibit cancer cell proliferation and induce apoptosis. - Rituxan +CHOP · Oncology
Rituxan is a monoclonal antibody that targets and depletes CD20-positive B cells, while CHOP is a chemotherapy regimen that includes cyclophosphamide, doxorubicin, vincristine, and prednisone.
Phase 2 pipeline
- AC591 · Immunology
AC591 is a small molecule inhibitor of the PI3K delta subunit. - Esomeprazole sodium for injection · Gastroenterology
Inhibits the H+/K+ ATPase enzyme - F520 · Diabetes
F520 is a small molecule that targets the SGLT2 receptor. - Rulonilimab · Other
Phase 1 pipeline
- Dronedarone Hydrochloride Tablets
- F182112
- F527
- LNF2007
- Nalfurafine Hydrochloride Orally Disintegrating Tablets
- Remitch®
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: